DHEA (Dehydroepiandrosterone): Evidence Review

DHEA (dehydroepiandrosterone) is one of the most widely marketed supplements in the hormonal health and anti-ageing space, yet the gap between its popular reputation and what the clinical evidence actually supports is substantial. This entry separates the approved, evidenced use of DHEA from the broader range of claims made for oral supplementation, which is where most consumer products sit.

What it is

Dehydroepiandrosterone is a steroid hormone produced primarily by the adrenal glands, with smaller contributions from the gonads and brain. It is the most abundant circulating steroid in humans and functions as a precursor to both androgens and oestrogens, including testosterone and oestradiol. Rather than acting directly through its own receptor, DHEA is converted peripherally in tissues into active sex hormones, with the nature and extent of that conversion depending on the tissue, the enzymes present, and the individual's hormonal environment.

DHEA levels peak in early adulthood, typically in the mid-20s, and then decline progressively with age. By the time a person reaches their 70s, circulating DHEA may be 10 to 20 percent of peak levels. This decline has led to the hypothesis that restoring DHEA could reverse or delay age-related changes in hormone-dependent tissues, a theory that has driven decades of research and a sizeable consumer supplement market. DHEA is also available in a sulphated form, DHEA-S, which serves as a circulating reservoir that tissues can draw on and is the form typically measured in blood tests.

DHEA is sold as an oral dietary supplement in the United States and available over the counter in several other markets, though it is regulated as a prescription medicine in the United Kingdom, Europe, and Australia. A separate prescription product, intravaginal prasterone (Intrarosa), contains synthetic DHEA and is approved by the FDA and regulatory bodies in several other countries specifically for the treatment of moderate to severe dyspareunia due to vulvovaginal atrophy in postmenopausal women. These two forms — oral supplement and prescription intravaginal insert — have very different evidence bases and should not be conflated.

What the evidence shows

The clearest and most clinically grounded evidence for DHEA concerns intravaginal prasterone in postmenopausal women with vulvovaginal atrophy. Two pivotal placebo-controlled trials enrolling a combined 716 postmenopausal women demonstrated that daily intravaginal prasterone at 6.5 mg for 12 weeks produced statistically significant improvements in dyspareunia severity compared with placebo, with reductions of approximately 0.36 to 0.40 severity score units over placebo on a four-point scale. The treatment also improved vaginal cytology and reduced vaginal pH. These improvements are statistically significant but modest in magnitude, and their clinical relevance varies between individuals. Individual symptom scores for vaginal dryness and irritation were similar between prasterone and placebo groups in some analyses, and the placebo response in this indication is substantial. Regulatory approval reflects demonstrated efficacy over placebo rather than superiority over existing first-line treatments. Current evidence suggests intravaginal prasterone has similar efficacy to low-dose vaginal oestrogen without clear superiority, and it is best understood as an alternative rather than a first-line option.

For oral DHEA supplementation, the picture is considerably less clear. Meta-analyses confirm that oral DHEA raises circulating oestradiol and testosterone in postmenopausal women, with one 2024 meta-analysis of 21 trials reporting weighted mean differences of approximately 7.86 pg/mL for oestradiol and 24.31 ng/dL for testosterone above placebo. Despite consistent increases in circulating sex hormones, these changes do not reliably translate into meaningful improvements in clinical outcomes. The clinical significance of raising circulating hormone levels by these amounts is uncertain given that the conversion and biological activity of those hormones varies substantially between individuals and tissues. Heterogeneity across trials is high, complicating interpretation further.

Beyond biomarker effects, evidence for oral DHEA's clinical benefits is limited and largely inconsistent. Evidence on bone mineral density is mixed, with some meta-analyses showing modest effects on hip BMD in women but not in men and no consistent signal at the clinically important lumbar spine. A Cochrane review of DHEA supplementation for cognitive function found no support for improvement in memory or other cognitive outcomes in healthy older adults. Evidence on mood and depression is preliminary, with some suggestion of benefit in populations with documented low DHEA, but trial samples are small, heterogeneity is high, and placebo effects in this domain are well established. Anti-ageing, immune, cardiovascular, and body composition claims rest largely on mechanistic reasoning and small, short-duration trials.

Five questions

Does low DHEA status cause harm? Low circulating DHEA-S is associated in observational data with poorer outcomes in ageing populations across several domains, including bone density, cognition, and vitality. However, association does not establish causation, and intervention trials have not consistently shown that restoring DHEA levels to younger-adult ranges produces corresponding clinical improvements. Low DHEA in the context of adrenal insufficiency is a more specific clinical situation where there may be a case for replacement, but this is distinct from the age-related decline seen in otherwise healthy individuals.

Does supplementation prevent disease? There is no established evidence that oral DHEA supplementation prevents any specific disease. Anti-ageing claims are not supported by trial data. The intravaginal route addresses a specific genitourinary symptom rather than disease prevention. Long-term data on whether DHEA supplementation reduces fracture risk, cardiovascular events, or cognitive decline are absent.

Does it affect biomarkers? Oral DHEA reliably raises circulating DHEA-S, oestradiol, and testosterone in postmenopausal women. Effects in premenopausal women, men, and younger adults are less consistent, partly because endogenous DHEA production is already more active in these groups and the conversion environment differs. Biomarker changes do not reliably translate to clinical benefit and should be interpreted with caution, particularly given the uncertain implications of raising sex hormone levels in individuals with or at risk of hormone-sensitive conditions.

Does it help clinical populations? The strongest evidence applies to postmenopausal women with vulvovaginal atrophy using the intravaginal route. In women with adrenal insufficiency, DHEA replacement may address a deficiency-driven deficit, though this sits within a specialist clinical context. In other clinical populations, including those with mild cognitive impairment, depression, or osteoporosis, evidence is inconsistent and trials generally too small or too short to draw firm conclusions.

Does it benefit healthy individuals? Evidence is insufficient to support oral DHEA supplementation in healthy younger or middle-aged adults. The theoretical basis is plausible, but intervention trials have not demonstrated consistent clinical benefit in people with normal DHEA levels. The age-related decline in DHEA does not appear sufficient, on current evidence, to justify supplementation as a routine health measure.

Individual variation

Response to oral DHEA supplementation varies considerably. Postmenopausal women show more consistent and pronounced biomarker responses than premenopausal women or men, likely because postmenopausal women have lower endogenous sex hormone production and greater dependency on peripheral conversion of adrenal precursors. Among postmenopausal women, responses are generally more pronounced with increasing age, higher doses, and longer duration. Baseline DHEA-S status may also modulate response, with those starting from lower levels potentially showing greater change in hormonal biomarkers, though this has not been consistently demonstrated to predict clinical benefit.

Conversion of DHEA to active sex hormones is tissue-specific and depends on the activity of local enzymes, meaning that circulating hormone levels provide only a partial picture of biological activity. Genetic variation in enzymes such as 3-beta-hydroxysteroid dehydrogenase and aromatase may influence individual response, though clinical data on this are limited. In the context of intravaginal prasterone, systemic absorption is low and hormone levels remain within the postmenopausal range, which is considered a safety advantage over oral systemic supplementation.

The absence of meaningful clinical trial data in premenopausal women, younger adults, and most male populations makes it difficult to extrapolate findings from postmenopausal female trials to these groups. Claims about DHEA's benefits in younger populations or in men are largely extrapolated from observational associations or mechanistic reasoning rather than trial evidence.

Testing and status assessment

Serum DHEA-S is the standard measurement of DHEA status, as it is more stable than DHEA itself and reflects the circulating reserve available for peripheral conversion. Reference ranges are age-adjusted, as DHEA-S declines substantially across adulthood. A result that appears low relative to broad population norms frequently reflects normal ageing rather than pathological deficiency, and a low DHEA-S in the absence of clinical symptoms or adrenal pathology does not in itself constitute an indication for supplementation.

Testing DHEA-S is most clinically relevant in the context of suspected adrenal insufficiency, where it forms part of a broader hormonal evaluation, or in women with features of androgen excess or deficiency that cannot be explained by other causes. In otherwise healthy adults who are not experiencing specific symptoms, routine DHEA-S testing has limited clinical utility given the uncertain relationship between circulating levels and health outcomes when intervention trials have not consistently demonstrated benefit from correction.

Saliva testing for DHEA is available commercially but is less standardised than serum measurement and not recommended as a primary diagnostic tool. Home testing kits measuring DHEA in saliva or dried blood spots are available but not validated for clinical decision-making.

Safety

Oral DHEA supplementation at doses of 25 to 50 mg daily is generally considered safe in short-term use, with most adverse effects attributable to androgenic activity. Acne, oily skin, and unwanted hair growth are the most commonly reported issues, particularly at higher doses and in women who are more sensitive to androgen exposure. These effects are dose-dependent and generally reversible on stopping supplementation.

Because DHEA is a precursor to both oestrogens and androgens, there is a meaningful concern about its use in individuals with hormone-sensitive conditions. Intravaginal prasterone is contraindicated in women with a known or suspected history of breast cancer, as oestrogen is a metabolite of prasterone. The same precaution applies to oral DHEA, and women with a personal or strong family history of hormone-sensitive cancer should discuss DHEA use with a clinician before proceeding. More broadly, oral DHEA introduces variability in systemic hormone exposure that is not routinely monitored, which may carry risk in susceptible individuals.

Long-term safety data for oral DHEA supplementation are limited. Most trials are twelve weeks or less in duration, and the safety profile beyond two years in community populations is not well characterised. DHEA can interact with drugs metabolised through the cytochrome P450 pathway, and there is a potential for interaction with anticoagulants, antidiabetic medications, and other hormonal therapies. Women taking hormone replacement therapy should consult a prescriber before adding oral DHEA, as combined use may produce additive effects on circulating hormone levels that are difficult to predict or monitor. Oral DHEA should be avoided during pregnancy and breastfeeding in the absence of safety data.

What can reasonably be concluded

The most clearly evidenced use of DHEA is intravaginal prasterone for moderate to severe dyspareunia due to vulvovaginal atrophy in postmenopausal women. This indication is supported by regulatory approval and placebo-controlled trial data, though the effect sizes are modest, the placebo response is substantial, and current evidence does not demonstrate superiority over low-dose vaginal oestrogen. The intravaginal route is also considered safer than oral supplementation given low systemic absorption and maintenance of hormone levels within the postmenopausal range.

Oral DHEA supplementation raises circulating sex hormone biomarkers in postmenopausal women, but despite consistent biomarker changes, clinical outcomes across bone density, cognitive function, mood, sexual function, and general well-being are inconsistent and insufficient to support broad recommendations. The large gap between marketing claims and trial evidence is characteristic of this category, and caution is warranted given the implications of raising circulating androgens and oestrogens in populations that may include individuals with hormone-sensitive health histories.

Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.